Myeloid Therapeutics, Inc., a clinical stage mRNA-immunotherapy company, completed a $73 million financing led by Hatteras Investment Partners, with participation from new investors ARCH Venture Partners and Moore Strategic Ventures. Existing investors, including Newpath Partners, 8VC and Alexandria Venture Investments, also participated.

Proceeds from the financing will support the continued clinical development of MT-101, Myeloid’s lead cell therapy program in Phase 1/2 for T cell lymphoma, and will accelerate the development of MT-302, a first-in-class TROP2-FcA mRNA-LNP product, into a Phase 1/2 study for TROP2-expressing tumors.  Additional in vivo programming candidates are also advancing to the clinic. 

“Myeloid continues to make significant progress across all aspects of our business,” said Daniel Getts, CEO of Myeloid.  “We are pioneering the convergence of immunology and RNA science to build a clinical-stage portfolio of products, starting with the significant unmet needs of cancer patients. We are pleased that such high-quality investors have joined with us to accelerate this effort.”

Clay Thorp, general partner at Hatteras, said, “Hatteras focuses on investments in cutting-edge companies that are disrupting the status quo and accelerating the pace of innovation.  We are highly encouraged by the innovation, execution and clinical development progress demonstrated by Myeloid.  We are proud to support this field-leading company through its next phase of growth and are optimistic that these approaches will drive a meaningful clinical outcome for patients.”